Generating survival times using Cox proportional hazards models with cyclic time-varying covariates, with application to a multiple-dose monoclonal antibody clinical trial
Yunda Huang, Yuanyuan Zhang, Zong Zhang, Peter B. Gilbert

TL;DR
This paper develops simulation methods for generating survival times influenced by cyclic, time-varying covariates in clinical trials, specifically modeling drug concentration effects with threshold-based protection levels.
Contribution
It introduces two novel simulation approaches for Cox model-based survival data with cyclic, threshold-dependent covariates in multiple-dose settings.
Findings
Simulated data accurately reflect cyclic covariate patterns.
Methods perform well under Cox proportional hazards assumptions.
Approaches are validated through extensive simulations.
Abstract
In two harmonized efficacy studies to prevent HIV infection through multiple infusions of the monoclonal antibody VRC01, a key objective is to evaluate whether the serum concentration of VRC01, which changes cyclically over time along with the infusion schedule, is associated with the rate of HIV infection. Simulation studies are needed in the development of such survival models. In this paper, we consider simulating event time data with a continuous time-varying covariate whose values vary with time through multiple drug administration cycles, and whose effect on survival changes differently before and after a threshold within each cycle. The latter accommodates settings with a zero-protection biomarker threshold above which the drug provides a varying level of protection depending on the biomarker level, but below which the drug provides no protection. We propose two simulation…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Code & Models
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsStatistical Methods in Clinical Trials · Protein purification and stability · Monoclonal and Polyclonal Antibodies Research
